DMT310

DMT310 is a complex natural product containing multiple active components and is currently under development for the treatment of moderate to severe acne.  It contains a rare variant of freshwater sponge that is harvested from a protected location, under specific environmental conditions to ensure the sponge comprises the optimal product characteristics.  After processing, the sponge powder contains precisely sized and shaped silica spicules that upon application may help exfoliate the skin, promote collagen production, open closed comedones and facilitate penetration of the sponge’s naturally occurring chemical compounds. These chemical compounds have been shown, in-vitro, to have both antimicrobial and anti-inflammatory properties which we believe play a role in the treatment of acne.  We believe the combination of the spicules with the unique chemical compounds within the sponge, may lead to an acne product that only needs to be applied once per week and will have a faster time to treatment than currently available products.

DMT400

DMT400 is a novel combination regimen using our unique DMT310 sponge product to increase permeability of the skin, facilitating the dermal delivery of macromolecules. DMT310’s millions of microscopic needle-like spicules penetrate through the stratum corneum, creating microchannels in the skin, allowing a topically applied macromolecule to be massaged onto the skin and penetrate into the dermis. DMT400’s combination regimen produces many potential benefits over the use of injections, including a potential for lower systemic exposure allowing for the use of biologics in a milder patient population, and greater patient acceptance due to the injection-free delivery. The DMT400 regimen can be used for the safe and effective topical delivery of biologic molecules for numerous skin diseases and cosmetic applications, such as hyperhidrosis, psoriasis, acne, rosacea and overall skin quality.

DMT410

DMT410 is our development program using our DMT400 combination regimen. We conducted a proof of concept, Phase 1 clinical trial using DMT310 in combination with BOTOX® for the treatment of primary axillary hyperhidrosis. In this study, 10 patients received application of reconstituted DMT310 to each axilla, which after being washed off, was followed by a topical application of BOTOX® to each axilla. The treatment was well tolerated, and a majority of patients saw a reduction in sweat production similar to results seen from using injections of BOTOX®.